Geoffrey Collett, MD
Ophthalmology · Bellaire, TXNPI 1598296246
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Biotissue Holdings Inc. at 24.9% of the total. 2025 is the largest year on record at $7,256, more than ten times the $327 reported in 2021. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $99.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$5K
- Tarsus Pharmaceuticals, Inc.$4K
- Alcon$2K
- Carl Zeiss Meditec USA, Inc.$2K
- Lumenis BE Inc$2K
- AbbVie$1K
- plus $4K from 15 others
Across 1 payment — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$4K
What the payments were for
- Consulting fees$3,00016%
- Travel & lodging$5,99931%
- Food & beverage$10,24253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 36 | $4,790 |
| Tarsus Pharmaceuticals, Inc. | 23 | $3,798 |
| Alcon | 29 | $2,395 |
| Carl Zeiss Meditec USA, Inc. | 9 | $2,055 |
| Lumenis BE Inc | 1 | $1,500 |
| AbbVie(2 entities) | 36 | $1,102 |
| Sight Sciences, Inc. | 8 | $709 |
| Bausch & Lomb Americas Inc. | 9 | $561 |
| Rayner Intraocular Lenses Limited | 6 | $547 |
| Rxsight Inc | 6 | $376 |
| Glaukos Corporation | 6 | $328 |
| Regeneron Healthcare Solutions, Inc. | 4 | $244 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $211 |
| Dompe US, Inc. | 4 | $193 |
| Oyster Point Pharma, Inc. | 4 | $157 |
| Astellas Pharma US Inc | 1 | $122 |
| Genentech USA, Inc. | 2 | $53 |
| Novartis | 2 | $32 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$2,649
- AmnioGraft$2,523
- CIRRUS HD-OCT$1,774
- ARTEVO 800$1,611
- IOLMaster 700$1,611
- VERACITY SURGICAL$1,611
- VisuMax$1,611
- optilight$1,500
- OMNI(R) SURGICAL SYSTEM (US)$540
- RayOne EMV$487
- RayOne Spheric$487
- RayOne Aspheric$487
- RAYNER CATARACT SET 1$375
- Rhopressa$364
- Rocklatan$364
- SION SURGICAL INSTRUMENT$283
- DURYSTA$235
- RXSIGHT CONTACT LENS$221
- RXSIGHT INJECTOR CARTRIDGE$221
- RXSIGHT INJECTOR HANDPIECE$221
How this compares
$19,241 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 70 | $38,536 |
| RestasisCyclosporine | 35 | $37,565 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $26,106 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $19,660 |
| RhopressaNetarsudil Mesylate | 24 | $11,606 |
| Prednisolone Acetate | 220 | $9,477 |
| Travoprost | 32 | $8,417 |
| Latanoprost | 571 | $7,979 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $6,259 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,646 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 170 | $3,035 |
| Brimonidine Tartrate | 140 | $2,813 |
| Dorzolamide Hcl | 72 | $2,359 |
| Ciprofloxacin Hcl | 147 | $1,488 |
| Timolol Maleate | 60 | $1,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,102 | $95,761149 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $23 | $37,71252 claims |
| AlconSimbrinza | $2,395 | $6,25914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$1.5M
- Otis WaltonBellaire$311K
- Richard YeeBellaire$195K
- Prethy RaoBellaire$85K
- Hasenin Al-KhersanBellaire$76K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.